Volume 140, Issue 4, Pages 1189-1198.e1 (April 2011) Zinc Monotherapy Is Not as Effective as Chelating Agents in Treatment of Wilson Disease Karl Heinz Weiss, Daniel Nils Gotthardt, Daniela Klemm, Uta Merle, Daniela Ferenci–Foerster, Mark Schaefer, Peter Ferenci, Wolfgang Stremmel Gastroenterology Volume 140, Issue 4, Pages 1189-1198.e1 (April 2011) DOI: 10.1053/j.gastro.2010.12.034 Copyright © 2011 AGA Institute Terms and Conditions
Figure 1 (A) Discontinuation of treatment due to (A) any cause, (B) adverse events, (C) treatment failure, and (D) OLT or death analyzed by the Kaplan–Meier estimation. Gastroenterology 2011 140, 1189-1198.e1DOI: (10.1053/j.gastro.2010.12.034) Copyright © 2011 AGA Institute Terms and Conditions
Figure 2 Course of AST and γ-GT levels of patients under zinc treatment, grouped by treatment response. Patients with a nonresponse to zinc treatment showed significantly higher liver enzyme levels. Gastroenterology 2011 140, 1189-1198.e1DOI: (10.1053/j.gastro.2010.12.034) Copyright © 2011 AGA Institute Terms and Conditions
Figure 3 Course of serum and urinary zinc levels of patients under zinc treatment, grouped by treatment response. No statistically significant differences were observed, suggesting an adequate compliance in the nonresponder group. Gastroenterology 2011 140, 1189-1198.e1DOI: (10.1053/j.gastro.2010.12.034) Copyright © 2011 AGA Institute Terms and Conditions